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To better understand the role of specific residues within the duck hepatitis B virus (DHBV) pre-S protein in neutralization
and infectivity, we have selected and identified pre-S variants which escape neutralization. A highly neutralizing monoclonal
antibody (Mab 900) which recognizes an epitope 83IPQPQWTP90 localized previously on the DHBV pre-S protein, within a
region suspected to mediate the virus interaction with hepatocytes, was used as immune pressure. After only two in vivo
neutralization rounds with Mab 900, five different pre-S mutant genomes were identified, which harbored point mutations
affecting only proline residues located at position 90 within this epitope (83IPQPQWTP90) and/or at a distance at position 5.
We have shown that a single (P5L) or double proline (P5L / P90H) substitution affect neither virus replication capacity nor
in vivo infectivity. However, the P5 mutation reduces mutant recognition by Mab 900 twofold, while the substitution of both
prolines 5 and 90 almost completely abolishes mutant P5L / P90H reactivity with this Mab and leads to a decrease of
neutralization. Therefore we describe here an experimental system which allows rapid in vivo selection and identification
of DHBV pre-S variants and provide evidence that residues within and at a distance from the neutralization epitope are
important in DHBV neutralization but do not affect its replication capacity and infectivity. q 1997 Academic Press
ing antibodies is also suspected for HBV variants whichINTRODUCTION
cannot express pre-S2 protein (Fernholz et al., 1991).
However, the mechanisms of emergence of such hep-The neutralizing response against hepatitis B virus
adnaviruses escape variants, their accumulation, and(HBV) is directed against three distinct cocarboxytermi-
their biological significance are far from clear, due essen-nal envelope proteins designated pre-S1, pre-S2, and S
tially to the lack of suitable experimental systems(Neurath and Kent, 1985). The existence of HBV neutral-
allowing their analysis. The closely related duck hepatitisization escape variants has been suspected for many
B virus (DHBV) represents the only model in which hep-years, although only development of PCR amplification
adnavirus escape variants can be easily studied, sincemethods allowed the recent identification of mutations
the neutralization and the relation between a single muta-within the viral envelope gene. The emergence of HBV
tion and its biological or pathobiological effect can beescape variants was first reported in children which de-
investigated both in primary duck hepatocyte culturesveloped breakthrough infections following passive-active
and in vivo in ducklings (Tuttleman et al., 1986; Li et al.,vaccination against HBV (Carman et al., 1990; Harrison
1989; Lambert et al., 1990). In addition, study of suchet al., 1991; Okamoto et al., 1992; Karthigesu et al., 1994).
DHBV variants is an interesting approach for understand-These variants have point mutations within the surface
ing the mechanisms of neutralization and virus host cellgene leading to the loss of the immunodominant ‘‘a’’ de-
interaction, as has been shown for poliovirus, rhinovirus,terminant of HBsAg against which the vaccine-induced
influenza virus, and HIV (for review Dimmock, 1993). Inanti-HBs response is mainly directed (Carman et al.,
this regard the mechanism of DHBV neutralization is1990; Harrison et al., 1991; Okamoto et al., 1992). Such
poorly understood, and it is not clear whether the neutral-mutations, resulting in amino acid substitutions, are re-
ization epitopes are identical to the functional virus re-sponsible for a marked effect on antigenicity and affect
ceptor site. Two major proteins, pre-S (36 kDa) and S (18the binding of protective anti-HBs antibody. Similar neu-
kDa), have been identified within the DHBV envelope,tralization escape variants have also been reported in
neither being glycosylated. The major neutralization epi-transplant patients treated with monoclonal anti-HBs an-
topes have been mapped by us and others within the N-tibodies to prevent liver graft infection (McMahon et al.,
terminal portion (aa 58–107) of DHBV pre-S using mono-1992). The escape from immune elimination by neutraliz-
clonal and polyclonal antibodies (Lambert et al., 1991;
Yuasa et al., 1991; Chassot et al., 1993).
In the present study, a highly neutralizing monoclonal1 To whom correspondence and reprint requests should be ad-
antibody (Mab 900), which recognizes an epitopedressed at INSERM U 271, 151 Cours Albert Thomas, 69424 Lyon cedex
03, France. Fax: (33) 72681971. E-mail: U271@lyon 151. inserm. fr. (IPQPQWTP) localized previously between aa 83 and 90
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TABLE 1on the DHBV pre-S protein (Chassot et al., 1993), was
used as immune pressure for the in vivo selection of Synthetic Oligonucleotide Primers Used for PCR Amplification and
DHBV variants. This epitope is located within the region DNA Sequencing
of DHBV pre-S which has recently been shown to be
Name Direction Position Sequence (5* 3*)critical for interaction with the putative virus receptor on
hepatocytes (Kuroki et al., 1994; Tong et al., 1995).
PS1 Forward 628–647 CCAAAGTATCCTGACAATGTG
We report here the in vivo selection of DHBV pre-S PS2 Forward 893–912 AGGGACTTTGACATGGTCAG
variants after only two consecutive neutralization PS3 Forward 1162–1181 AGTGGAAGCTACAACCCGGG
PA1 Reverse 1463–1485 CCCACGGGCAAGATCCTACGTArounds in the presence of the highly neutralizing Mab
PB Forward 1066–1082 ACTCCCGAGGAAGACCAA900. We have identified two proline residues located
within and at a distance from the neutralization epitope
Note. The pre-S region is located between nucleotides 801 and 1283
(83 – 90) which are important for virus recognition by on the DHBV genome, numbering according to Mandart et al. (1984).
neutralizing Mab but do not affect its replication capac- The monoclonal antibody 900 recognizes an epitope coded by nucleo-
tides 1047 to 1070.ity and infectivity.
MATERIALS AND METHODS
considered effective when the reduction of viremia titer
Virus was at least 50% in the group of ducklings which received
virus–Mab mixture compared to the control group (Dim-The inoculum used in this study, quantified into 6 1
mock, 1984; Lambert et al., 1991; Chassot et al., 1993).109 virus genome equivalents/ml (vge/ml), derived from
cloned and sequenced DHBV (Mandart et al., 1984),
DHBV DNA extraction and PCR amplificationwhich was passaged six times in vivo (Lambert et al.,
1990). Viral DNA was extracted from duck serum (50 ml) or
transfected LMH cells supernatant (500 ml) by proteinaseAnimals
K (50 mg/ml) digestion in the presence of 0.5% sodium
Three-day old DHBV-free Pekin ducklings were intra- dodecyl sulfate; 5 mM Tris; 0.5 mM EDTA, for 2 hr at 567
venously (iv) inoculated with DHBV-positive serum (6 1 followed by proteinase K inactivation for 10 min at 957.
106 vge/duck). Viremia was followed daily during the first Thereafter, Taq DNA polymerase buffer (Promega) (50
week postinoculation and therafter every 2 days, by mM KCl, 10 mM Tris–HCl, pH 9.0, 0.1% Triton X-100)
quantitative dot blot hybridization as described pre- and 0.25% Tween 20, 0.25% NP40, 1.5 mM MgCl2 final
viously (Cova et al., 1986). concentration were added. Primers PS1 and PA1 (Table
1) were designed to amplify the entire DHBV pre-S region
Antibodies (nt 628 to 1485). Target sequences were amplified by
PCR in a 50-ml reaction mixture containing 2.5 units ofThe rabbit polyclonal antiserum was raised against
Taq polymerase (Promega), 200 mM deoxynucleotide tri-the first 131 amino acids of the DHBV pre-S envelope
phosphate (dNTP), 100 pmol of each primer, 1 1 Taqprotein (Lambert et al., 1991). The murine monoclonal
buffer (Promega). After a 5-min denaturation at 957, sam-antibody (Mab) 900 specific to the DHBV pre-S protein
ples were submitted to 35 cycles: 957 (30 sec), 557 (30used in this study has been characterized previously
sec), and 727 (1.5 min) followed by a final extension step(Chassot et al., 1993). The epitope recognized by Mab
of 10 min at 727 using a DNA thermal cycler (Perkin –900 has been mapped between amino acids 83 to 90
Elmer, Cetus, U.S.A.) (Duflot et al., 1995). The amplifiedusing peptide scanning (Chassot et al., 1993).
DNA fragment (857 bp) was first visualized on ethidium
bromide-stained 2% agarose gels. The specificity of am-In vivo neutralization of DHBV infectivity
plification was further confirmed by hybridization with the
The in vivo neutralization test was performed as de- radiolabeled internal probe PB (nt 1066–1082, Table 1)
scribed previously (Lambert et al., 1991). Briefly two as described previously (Cova et al., 1994).
groups of four ducklings were iv inoculated with DHBV
positive serum (6 1 106 vge/duck) preincubated over- Cloning and sequencing of PCR-amplified product
night at room temperature, with either PBS or unrelated
ascite fluid (controls) or with Mab 900 ascite fluid. Vire- To search for the presence of mutations within DHBV
pre-S, the 857-bp DNA fragment amplified from duck se-mia was followed for 3 weeks by quantitative dot blot
hybridization (Cova et al., 1986). The mean viremia titers rum was first cloned into pGEM-T vector (Promega). Ten
independent clones were analyzed for the completeof each group of four ducklings, based on individual bird
vge values at its viremia peak, were used to calculate DHBV pre-S sequence (nt 628 to 1485) using the three
primers PS1, PS2, and PS3 (Table 1). Sequencing wasthe percentage of neutralization of infection as described
previously (Lambert et al., 1991). The neutralization was carried out by the dideoxynucleotide chain termination
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method (Sanger et al., 1977) using the Sequenase Ver- amplification as described above. Direct sequencing was
performed on PCR amplified DHBV pre-S region usingsion 2.0 DNA Sequencing Kit (USB, Amersham). Pre-S
mutations are designated by the one-letter code for the Sequenase PCR Product Sequencing kit (U.S.B., Amer-
sham). As a negative control, we have added 100 ng ofwild-type amino acid, the position in p36 of the substi-
tuted residue, and the substituted amino acid. pCMV-DHBV plasmid to non transfected cell superna-
tants prior to Dnase I treatment, immunoprecipitation,To analyze the impact of mutations on DHBV replica-
tion, each mutated PCR fragment (857 bp) was inserted and PCR amplification.
into the DHBV genome as follows: the pGEM-T plasmid
was digested by XhoI and EcoRV and the 492-bp frag- Infectivity of pre-S mutants in vivo and reactivity
in ELISAment obtained was then inserted into pGEMEX.1-DHBV
cleaved by XhoI and EcoRV. This vector was submitted
The supernatants from the transfected LMH cells wereto BglII–XhoI digestion. The resulting 821-pb BglII– XhoI
iv inoculated into 3-day-old ducklings (2 1 106 vge/duck-fragment (nt 391 to 1212) was subcloned into the pCMV-
ling). Two successive in vivo passages were performedDHBV plasmid kindly provided by C. Seeger (Institute for
in order to prepare a stock of DHBV-positive sera forCancer Research, Fox Chase Cancer Center, Philadel-
each mutant, and virus particles were concentrated fromphia, PA) in which transcription of the DHBV DNA prege-
duck serum by centrifugation through 10–20% sucrosenome-encoding sequence is driven by the CMV promoter
as described above. Direct ELISA was carried out essen-(Condreay et al., 1990; Calvert and Summers, 1994).
tially as described previously (Lambert et al., 1990) with
slight modifications. Briefly, serum concentrated virus
Expression and detection of mutant virions in LMH particles (400 ng) diluted in 100 ml of 0.1 M carbonate
cell cultures buffer (pH 9.5) were coated overnight at room tempera-
ture onto microtiter plates (Falcon, Pro-bind). Free proteinTransfections were carried out using the avian hepa-
binding sites were blocked with 200 ml of PBS–caseinetoma cell line, LMH (Kawaguchi et al., 1987), in 60-mm
(3%) at 377 for 1 hr. Plates were then washed twice indishes by the calcium phosphate method with 10 mg of
PBS buffer containing 0.1% Tween 20 (PBS–Tween). AfterDNA per dish, as described (Condreay et al., 1990). Virus
incubation at 377 for 1 hr with the rabbit anti-DHBV pre-release was monitored by dot blot hybridization of the
S serum (diluted 1002 to 1007 in PBS–Tween) or withDNase I-treated (100 mg/ml, 30 min, 377) cell culture su-
Mab 900 ascite fluid (diluted 1002 to 1007), plates werepernatants harvested and clarified (2000 g, 10 min, 47)
washed three times, and peroxydase-coupled goat anti-daily for 5 days after transfection. Viral particles were
rabbit or anti-mouse IgG antibodies (Biosys) (dilutionconcentrated from cell culture medium (4 ml) by centrifu-
1:1000 in PBS–Tween) were added to each well followedgation at 120,000 g, 8 hr at 47 in a SW 41 rotor (Beckman)
by incubation for 1 hr at 377. The wells were washed fouron a 10–20% sucrose cushion and resuspended in 80
times in PBS–Tween, and the reaction was developedml of sample buffer (0.1 M Tris–HCl, pH 8.6; 1% sodium
with 100 ml of 0.15% orthophenylenediamine in sodiumdodecyl sulfate; 1% 2-mercaptoethanol; 10% glycerol). Im-
citrate buffer, pH 5 (0.1% H2O2) and stopped by additionmunoblotting and detection of pre-S protein was per-
of 50 ml of 2 N HCl, after 15 min of color development.formed as described previously (Lambert et al., 1990)
The optical density was read at 492 nm on a Anthosusing rabbit polyclonal anti-DHB pre-S serum (diluted
reader 2001.1:500), anti-rabbit peroxydase conjugate (Biosys, diluted
1:1000), and the ECL chemiluminescence detection kit
RESULTS(Amersham).
Viral particles were immunoprecipitated from trans- In vivo DHBV neutralization
fected cells supernatants with an anti-DHBV-S mono-
clonal antibody (7C.12) kindly provided by J. Pugh (Insti- Two successive in vivo neutralization rounds were per-
formed using as immune pressure a highly neutralizingtute for Cancer Research, Fox Chase Cancer Center, Phil-
adelphia, PA). Precipitation was carried out for 1 night Mab 900 specific for DHBV pre-S protein. During the first
neutralization round, two groups of ducklings were inocu-at 47 in the presence of monoclonal antibody and 50
ml of preswollen Protein G Sepharose (Pharmacia) per lated with equivalent amounts of DHBV positive serum (6
1 106 vge/duck) incubated either with PBS (controls groupmilliliter of DNase I (100 mg/ml, 30 min, 377) pretreated
medium. Protein G/anti-DHBV-S/viral particle complexes 1) or with Mab 900 (group 2). In the controls, viremia began
5 days postinoculation, reaching a peak at Days 6–7, fol-were pelleted, washed twice, and digested by proteinase
K (100 mg/ml) in the presence of 1% SDS to remove viral lowed by a strong decrease and fluctuation (Fig. 1A). A
similar pattern of viremia was obtained in another controlproteins. After digestion, a phenol/chloroform extraction
was performed and DHBV DNA was ethanol precipitated. group of ducks which received DHBV-positive serum prein-
cubated with an unrelated ascite fluid (data not shown).The DNA pellet was suspended in TE buffer (10 mM
Tris–HCL, pH 7.8, 1 mM EDTA) and submitted to PCR The onset of viremia in group 2, which received virus neu-
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control (group 1, Fig. 1A). However in an analogous experi-
ment using as inoculum a serum from another duckling
(D299, group 2), there was also an absence of neutralization
during a second neutralization round, but viremia titers ob-
tained in this experiment were comparable to those from
the control group 1 (data not shown).
Identification of mutations within DHBV pre-S
To investigate whether the absence of neutralization
as well as low viremia titers observed in ducklings from
group 3 and 4 inoculated with serum D280 reflect the
emergence of DHBV neutralization-escape mutants
with reduced replication capacities, we PCR-amplified,
cloned, and sequenced the entire pre-S region from con-
trol duckling serum (D281, group 1) and after one (D280,
group 2) and two rounds of neutralization (D206, group
4). Nine of 10 clones (Fig. 2B) from duckling D281 (group
1) which received DHBV-PBS were of wild-type se-
quence. Only one mutated clone was identified, harbor-
ing a C to T transition at nt 814, which leads to the
replacement of the proline at position 5 by a leucine
(P5L, Fig. 2B). After the first neutralization passage, the
majority (7/10) of analyzed clones from duckling D281
were of wild type and three were mutated. Two of those
harbored a single P5L mutation which was also identified
in the control group 1. In addition, a G to A transition
was identified in one clone leading to the substitution of
the tryptophan codon at position 88 within the epitope
(83IPQPQWTP90) by a stop codon (Fig. 2C). After two con-
FIG. 1. In vivo neutralization of DHBV infectivity with monoclonal secutive neutralization rounds, the mutant proportion
antibody 900. Viremia was followed by quantitative dot blot hybridiza- was dramatically increased since all 10 of 10 analyzed
tion as described under Materials and Methods. (A) First neutralization
clones harbored mutations within the DHBV pre-S. Nineround: ducklings of groups 1 and 2 were inoculated with DHBV-positive
of them had point mutations affecting P90, located withinserum (6 1 106 vge/duckling) preincubated with PBS or Mab 900, re-
spectively. (B) Second neutralization round: serum of duck D280 (boxed) epitope 83IPQPQWTP90 (Fig. 2D). The mutations were C
from group 2 served as inoculum for this neutralization passage. Duck- to A transversions, either on the first base of codon 90
lings of groups 3 and 4 received virus-positive serum (D280) preincu- (CCC) or on the second one (CCC), leading respectively
bated with PBS or Mab 900, respectively.
to the conversion of proline to threonine (P90T) or to
histidine (P90H). In addition, one clone harbored a single
mutation affecting the P5 (P5L Fig. 2D), also identifiedtralized with Mab 900, was delayed, peaking 10 days post-
before and after the first neutralization passage (seeinfection, and decreased by 71% compared to the group 1,
above). Interestingly, 7 of 10 clones were doubly mutatedindicating an effective neutralization. In the second round
as they harbored point mutations at both P 5 and 90 (P5Lof neutralization, a serum sample from one duckling (D280) / P90H and P5L / P90T, Fig. 2D). Therefore, after twofrom group 2 was incubated with either PBS or Mab 900
rounds of neutralization, five different DHBV pre-S mu-and injected into ducklings (6 1 106 vge/duck) of groups
tants were identified which all had mutated proline resi-3 and 4, respectively. All ducklings developed detectable
dues located within (position 90) and/or at a distanceviremia. However, the peak of viremia was not delayed in
(position 5) from the epitope recognized by the Mab 900both group 4, which received virus-Mab mixture, and con-
used as immune pressure (Fig. 2D).trol group 3, which received DHBV alone (Fig. 1B). In addi-
tion, there was no significant difference between the mean
Replication capacity of pre-S mutants
viremia titers developed by ducklings from groups 3 and 4,
suggesting the absence of DHBV neutralization after two To investigate the effect of these mutations on virus repli-
consecutive passages in the presence of Mab 900. Overall cation, we have introduced the PCR-amplified and se-
viremia titers obtained in ducklings from groups 3 and 4 quenced pre-S DNA fragments into an infectious DHBV
which received serum from D280 after a first round of neu- clone driven by the CMV immediate early promoter. These
constructions, named P5L, P90T, P90H, P5L / P90T, andtralization (Fig. 1B) were significantly lower than those from
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TABLE 2
Replication Capacity, Infectivity, and in Vivo Neutralization of DHBV Pre-S Variants
DHBV detection
in transfected Nucleotide exchangec Amino acid exchangec In vivo
Transfected LMH cells In vivo neutralization
DHBV DNA supernatantsa infectivityb Posd Mut Rev Pose wt Mut Rev of DHBV infectivity f
WT / 4/4 5 P //
90 P
P5L / 4/4 814 CTA 5 P r L /
P5L / P90H / 4/4 814 CTA 5 P r L {
1069 CAC 90 P r H
P5L / P90T / 4/4 814 CTA 5 P r L NTR
1068 ACC r CCC 90 P r T r P
P90H / 4/4 1069 CAC r CCC 90 P r H r P NTR
P90T / 4/4 1068 ACC r CCC 90 P r T r P NTR
a For the assessment of replication, pCMV-DHBV plasmids containing the sequenced PCR DNA fragments were transfected into LMH hepatoma
cell line. Five days later, the excretion of DHBV virions into cell supernatants was analyzed as described under Materials and Methods. The DNA
sequence of the secreted mutant particles immunoprecipitated from DNase I-treated transfected cell supernatants were confirmed to be identical
to the respective constructions used for transfections.
b Number of DHBV DNA positive ducks/number of ducks inoculated with DHBV (6 1 106 vge/duck) from transfected LMH cells supernatants.
c Nucleotide and deduced amino acid sequence after sequencing of the entire DHBV pre-S region following in vivo passage (for details see
Materials and Methods and Results).
d The nucleotide (nt) number refers to its position within the DHBV pre-S gene according to Mandart et al. (1984). Changed nucleotide is underlined.
e The amino acid number refers to their position in the DHBV pre-S protein (36 kDa).
f Significant neutralization is taken to be a 50% or more reduction in serum viral DNA levels at the peak of viremia (Lambart et al., 1991); // 75
to 100% neutralization, / 50 to 75% neutralization, { 25 to 50% neutralization. NTR, not tested since found reverted. Mut, mutation; Rev, reversion.
P5L / P90H, coding for the corresponding DHBV mutant cells was observed for all five mutant plasmids as assessed
by DNA hybridization (data not shown). This was furthergenomes (Fig. 2D) were transfected into the LMH hepa-
toma cell line (Table 2). A progressive release of virus in confirmed by the detection of the 36-kDa DHBV pre-S pro-
tein in the supernatants from cells transfected with eachsupernatants harvested during 5 days from transfected
FIG. 2. Summary of sequence data. (A) Schematic representation of a portion of the wild-type pre-S gene. The epitope (aa 83–90) recognized
by the Mab 900 is indicated, the proline residues at positions 5 and 90 are boxed, and the tryptophan residue at position 88 is underligned. (B)
Sequence analysis of 10 clones derived from serum of duckling 281 (contol group 1) which received virus preincubated with PBS. (C) Sequence
analysis of 10 clones obtained from a serum sample of duck D280 (group 2), after the first round of neutralization. (D) Sequence analysis of 10
clones derived from duck D206 (group 4), after two rounds of neutralization. Substituted nucleotides and amino acids are printed in boldface type.
Mutations are designed by the one-letter code for the wild type, the position in the p36 of the substituted residue, and the substituted amino acid.
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of the pre-S mutants (Fig. 3 and data not shown). Altogether, Therefore, the single P5L and double P5L / P90H muta-
tions do not abolish virus infectivity.these results indicate that mutants P5L, P90T, P90H, P5L
/ P90T, and P5L / P90H released viral particles. To verify We next wanted to test whether the two consecutive
neutralization passages lead to the selection of mutantsthat the introduced mutations were maintained in the re-
leased virions, we have immunoprecipitated viral particles which retain infectivity but present a reduced replication
capacity. To this end we have followed the viremia infrom Dnase I-treated transfected cells supernatants. Direct
sequencing of the PCR-amplified entire DHBV pre-S region ducklings infected with two cloned mutants (P5L and P5L
/ P90H) and with the duck serum obtained after the(nt 628–1485) from these virions showed that the DHBV
DNAs were of the same sequence as the respective con- first neutralization passage (D204 and D203, group 3)
compared to the control virus (D281, group 1). As illus-structions used for transfection (data not shown). It seems
unlikely that remaining input DNA served as template for trated in Table 3, ducklings infected with these different
viruses have similar high levels of DHBV DNA as animalsPCR amplification, since we have demonstrated in a control
experiment (detailed under Materials and Methods) that infected with control virus. In addition the viremia peak
was not delayed in these different groups of ducks (TableDHBV plasmid added to nontransfected cell supernatant
prior to Dnase I digestion cannot be detected by PCR (data 3), indicating that the replication capacity of virions se-
lected after the first neutralization passage as well asnot shown). In addition the amplification of viral DNA was
performed on complete virions which were immunoprecipi- the two mutants cloned after the second neutralization
passage was similar to the control virus.tated prior to DNA extraction and PCR analysis.
Reactivity with anti pre-S antibodiesIn vivo infectivity of mutants
We next determined the reactivity of mutants P5L andThe transfected LMH cell supernatants obtained for
P5L / P90H with the Mab 900 and a polyclonal antieach of the five mutants were inoculated into groups of
DHBV pre-S serum. Sera from each four ducklings inocu-four ducklings. All four of four ducklings inoculated with
lated with mutants P5L and P5L / P90H, respectively,equivalent amounts of vge developed detectable viremia
were pooled, concentrated on a sucrose cushion, and(Table 2). Since the reversion of DHBV mutants to wild
used for an ELISA test. As shown in Fig. 4A, the reactivitytype has been reported in vivo (Li et al., 1989; Macrae
of mutants P5L and P5L / P90H with the polyclonalet al., 1991), we checked first whether the mutations were
antiserum was only slightly affected as compared to themaintained after the first passage in ducklings. Direct
wild-type virus. However, the reactivity of mutant P5L withsequencing of the entire pre-S region amplified by PCR
Mab 900 was twofold decreased, while it was drasticallyfrom infected duckling sera showed that mutants P90T
affected for the double mutant P5L / P90H (Fig. 4B).and P90H had reverted to proline at this position (Table
To test whether this decreased recognition of mutants2). In addition, a back-mutation of T to P at position 90
P5L and P5L / P90H by Mab 900 has also an impact onwas detected for the double mutant P5L / P90T (Table
virus neutralization, we have performed an in vivo neutral-2). For this reason these revertants were not further char-
ization test. The quantification of virus released into duck-acterized. In contrast, we have confirmed by direct se-
ling sera (Table 2) indicate a trend to a lower neutralizationquencing that infectious mutants P5L and P5L / P90H
for mutant P5L (65%), which was more marked for mutantwere maintained after two consecutive in vivo passages,
P5L / P90H (less than 50%) compared to the wild-typein the absence of neutralizing Mab without additional
virus (80%).sequence modifications in the pre-S region (Table 2).
DISCUSSION
Hepadnaviruses neutralization escape variants have
to date been described only for HBV, and there is no
data on such variants for animal hepatitis B viruses. In
addition little is known on naturally occurring DHBV enve-
lope variants since previously described pre-S mutants
were generated by site directed mutagenesis (Li et al.,
1989; Calvert and Summers, 1994; Lenhoff and Summers,FIG. 3. Immunoblotting analysis of DHBV pre-S protein from medium
1994). Here we describe an experimental system whichof LMH cells transfected with mutant genomes. Viral particles concen-
trated from transfected LMH supernatants were detected by rabbit for the first time allowed rapid in vivo selection and identi-
polyclonal antiserum specific for DHBV pre-S envelope protein as de- fication of DHBV pre-S variants using as immune pres-
scribed under Materials and Methods. Viral particles from LMH cells sure a highly neutralizing Mab specific to virus pre-S
transfected with wild-type DHBV DNA, P5L, P90H, P90T, and P5L /
protein. We have performed an in vivo neutralization,P90T (lanes 1 to 5, respectively). For comparison viral particles concen-
since our attempts to select DHBV variants in primarytrated from DHBV-positive duck serum were loaded in lane 6. Molecular
weights in kDa are indicated at the right. duck hepatocyte cultures using the same Mab 900 were
AID VY 8665 / 6a3e$$$243 07-02-97 12:08:32 vira AP: VY
297SELECTION OF DHBV ESCAPE VARIANTS
TABLE 3
Viremia Patterns Obtained in Ducklings Infected with DHBV-Positive Serum after One and Two Neutralization Rounds
Number of neutralization passages Duck Day of viremia Viremia titer Average viremia titer
Inoculuma with Mab 900 No. peak (vge/ml)b (vge/ml)c
D281 0 F407 6 99 1 108 71 1 108
F408 7 61 1 108
F409 5 53 1 108
D203 1 F410 6 115 1 108 96 1 108
F411 5 98 1 108
F412 5 77 1 108
D204 1 F413 5 147 1 108 114 1 108
F414 5 84 1 108
F415 5 112 1 108
P5L 2 F401 4 222 1 108 153 1 108
F403 5 84 1 108
P5L / P90H 2 F404 5 57 1 108 110 1 108
F405 5 126 1 108
F406 5 148 1 108
a For the assessment of the DHBV infectivity, sera from duckling D281 (control virus) before the first round of neutralization with Mab 900 and
from ducklings D203 and D204 after the first passage of neutralization were used to inoculate three groups of three birds (for details on serum
origins refer to Fig. 1). Sera from ducklings infected, respectively, with P5L or P5L / P90H obtained after transfection with corresponding cloned
mutant genome were used to infect two additional groups of ducks.
b Viremia titers were estimated by quantitative dot blot hybridization in duck serum as described under Materials and Methods.
c Vge value at the peak of infection of each bird were used to calculate average virema titer of each group.
unsuccessful, due probably to the lower sensitivity of the S region in DHBV neutralization, infectivity, and host–
cell interaction. All five mutant genomes carrying singlein vitro as compared to the in vivo test as demonstrated
previously (Lambert et al., 1991). (P5L, P90T, P90H) or double mutations (P5L / P90T,
P5L / P90H) were shown to release viral particles afterThe majority of nucleotide changes we have identified,
after two rounds of antibody selection, were point transfection into LMH cells which were subsequently
shown to be infectious in vivo in ducklings. However,mutations which affect the same P90 located on the
DHBV pre-S region within this neutralization epitope sequence analysis of the progeny virus revealed that
only two (P5L and P5L / P90H) were stable in vivo in(83IPQPQWTP90) recognized by Mab 900. Two other muta-
tions were identified after the first round of antibody se- the absence of the Mab used for the selection, while
the others reverted either to wild type or to P5L. Thelection, which lead to the substitution of distantly located
P5 residue and a stop codon in position 88, within this appearance of wild-type genotype can be related either
to reversion or to contamination with the wild-type DHBV.epitope. After the second neutralization round the propor-
tion of mutants was dramatically enriched since all 10 of This latter hypothesis seems unlikely since we have con-
firmed that the introduced mutations were maintained in10 clones were mutated. Interestingly, 7 of those har-
bored double mutations affecting both prolines residues the released virions which were immunoprecipitated
from Dnase I-treated cell fluids. We have demonstratedat positions 5 and 90. Since the mutated P5 was present
with a proportion of 1/10 in the DHBV-positive serum in a control experiment that under such conditions the
input DNA was completly removed. However, we cannotused as the initial inoculum and 2/10 after the first neu-
tralization passage, it is likely that the second mutation rule out that a small proportion of viral genomes had
reverted to wild type at this stage and has a selectiveat position 90 occurs on DHBV genomes which already
carried a mutated codon 5. Altogether, these results sug- advantage in the subsequent in vivo infections.
It was important to assess whether the identified muta-gest that, despite a relatively low hepadnavirus mutation
rate, DHBV pre-S variants, which are generated during tions within DHBV pre-S alter the mutants replication
capacity and infectivity. The mutations P5L and P90Hvirus replication, can be easily isolated in vivo after only
two selection passages with highly neutralizing Mab spe- of pre-S do not affect the amino acid sequence of the
overlapping polymerase gene, while the mutation P90Tcific to DHBV pre-S protein.
The study of variants selected after neutralization leads to the replacement of a conserved serine residue
by a tyrosine. We have shown that this substitution doestherefore appears to be a useful approach to better un-
derstanding the role of specific residues within the pre- not affect the synthesis and secretion of viral particles
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after two neutralization rounds, developed viremia titers
at least as high as those infected with control virus. This
contrasts with overall lower viremia titers that we have
observed after the first round of antibody selection. The
presence of defective genomes (such as W88/stop) iden-
tified after the first round of neutralization in the duck
serum D280 may contribute to the overall viremia titers
obtained during the second in vivo passage.
Although the P5L and P90H substitutions have no im-
pact on DHBV infectivity, the single mutation at P5 al-
ready affects the mutant P5L reactivity with Mab 900. In
addition, the double mutation of two distantly located P5
and P90 almost completly abolished mutant reactivity
with Mab 900 explaining the reduction of neutralization.
Since the identified mutations affect proline residues,
known to play an important role in protein secondary
structure, we suspect that a modification of pre-S confor-
mation is involved in variant selection. Whether P5L af-
fects the epitope at position 83 to 90 indirectly or whether
residues 5 and 90 are brought together in the three-
dimensional protein structure and are a part of the same
discontinuous conformational epitope, as described for
other viruses (reviewed by Brown, 1990), is actually not
known and awaits crystallography data on the pre-S pro-
tein.FIG. 4. Comparison of DHBV wild type and mutants P5L and P5L /
Altogether the experiments presented here indicateP90H reactivity with anti-pre-S sera. Viral particles were concentrated
that the proline at position 90 is critical for DHBV neutral-from serum of ducklings infected with DHBV wild type (WT), P5L, or
P5L / P90H respectively. Concentrated virions (400 ng) were coated ization by Mab 900, but that its substitution does not
onto microtiter plates and incubated with (A) polyclonal anti-DHBV pre- affect virus infectivity. This does not mean that the neu-
S serum or (B) Mab 900. Direct ELISA was performed as described
tralization epitope 83–90 is not involved in the interactionunder Materials and Methods using anti-rabbit or anti-mouse IgG per-
with the cell surface receptor. The role of other residuesoxydase conjugates. The results are expressed as optical density (OD)
within the epitope 83–90 in virus replication, neutraliza-at 492 nm versus Mab 900 or polyclonal antibodies log dilution.
tion, and virus host–cell interaction is currently being
investigated by site directed mutagenesis. The identifica-
tion of additional escape variants selected with Mabssince the mutation P90T was confirmed in immunopre-
cipitated virions following in vitro LMH transfection. In such as SD20 (Lambert et al., 1990), 2D1, 1H5 (Yuasa et
al., 1991), and IB10 (Cheung et al., 1989), which recognizeaddition, we have demonstrated that this serine to tyro-
sine substitution within the polymerase does not affect different neutralization epitopes within DHBV preS and
S protein will allow to better define the role of theseDHBV replication and infectivity since P90T mutants gen-
erated by site directed mutagenesis were infectious in envelope proteins in DHBV neutralization and the cell
entry pathway.primary duck hepatocyte cultures (manuscript in prepara-
tion).
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